These agents include bisphosphonates, osteoclast-inhibiting drugs, and cathepsin K inhibitors. Cancer patients receiving IV bisphosphonates have a 4-fold increased risk of ONJ, perhaps due to greater bioavailability of IV bisphosphonates (2).